Why Brilacidin will make billions of dollars IMO it may very likely be the next Aspirin. Ipix Profits and benefits beyond Covid 19 will be like a metaphor comparing the tip of an iceberg to the iceberg submerged below the water surface. Spoiler alert this a 5 minute read, but I feel very worth your while.First, I’ll discuss Aspirin and then give a corollary discussion for Brilacidin.
The aspirin we know came into being in the late 1890s in the form of acetylsalicylic acid when chemist Felix Hoffmann at Bayer in Germany used it to alleviate his father's rheumatism, a timeline from Bayer says. Beginning in 1899, Bayer distributed a powder with this ingredient to physicians to give to patients
Aspirin, the simple, white, headache reliever you buy over the counter has more health benefits than you may think. As a non-steroidal anti-inflammatory drug, it has many advantages. Current research is underway to discover the potential aspirin has as a cancer preventative. Taking aspirin as a preventative measure for a disease is not right for everyone. Each person’s tolerance for such a drug will differ. Therefore, it is essential to talk with your healthcare professional about taking aspirin for more than an average headache. Imagine a combo cocktail with aspirin and Kevetrin. Keep that in mind as you read about aspirin below.
The most common use of aspirin is for a headache. It works by inhibiting the production of prostaglandin by first inhibiting the COX-2 enzyme. That is a scientific way of saying that it relieves the pain caused by inflammation in the brain. Researchers recently discovered is that taking aspirin can be beneficial to memory and cognitive function. Tests spanning five years have shown an increase in memory scores in people taking aspirin the whole time. It also cuts the risk of Alzheimer’s disease by up to 55%. It works by breaking down the proteins that cause plaques in the area of the brain reserved for memories.
For years, physicians have prescribed aspirin to those with a high risk of having a heart attack or a stroke. This category is generally men and women over the age of 50. Heart attacks and strokes happen when the supply of blood to areas of the heart, or brain, is cut off. The obstruction in the artery can be a blockage, bubble, or buildup of substances formed within the body. Aspirin thins the blood, which then flows through the arteries easier. This symptom reduces the risk of blockages and therefore, heart attack or stroke.
Many studies look at the effect of taking regular aspirin has on the growth and spread of breast cancer cells. Test using mice showed that aspirin shrank the cancer cells and slowed the spreading of the tumor. In human trials, some women found low doses of aspirin reduce the risk of breast cancer by 30%. Low dose is the key here. Large amounts of aspirin on a regular basis can have serious, detrimental, reoccurring effects on your health.
Skin cancer is one of the most common diseases in the world. The number of cases of skin cancer in the USA has increased in recent years. Melanoma is the most dangerous kind of skin cancer. A study that lasted over 12 years found that women who take aspirin regularly may decrease the risk of melanoma. In these tests, the aspirin activated tumor-suppressant genes and promoted cell death. The longer individuals used aspirin, the lower the risk. Doctors do not recommend that everyone start taking aspirin and lay in the sun on a hot day. Melanoma depends on many other factors such as genetics, skin and sun behaviors.
Over 20,000 women will be diagnosed with ovarian cancer in the United States in just one year. The risk of liver and ovarian cancers drop through the use of aspirin. Aspirin works to blocks the production of the substance that makes platelets sticky; this activation of platelets helps tumors grow. Aspirin also has
anti-inflammatory properties, which reduce overall cancer risk. Studies are still ongoing to discover how aspirin reduces the risk of ovarian cancer, and scientists are confirming the findings.
Brilacidin and related compounds are protected under various composition and use patents. A patent was filed and is pending for the use of HDP-mimetics in the prophylaxis and/or treatment of inflammatory diseases of the gastrointestinal tract. Another patent for compounds for use in treatment of mucositis has been awarded numerous global protections.
Colorectal cancer is commonly known as colon cancer or rectal cancer. It is cancer of the colon and rectum. There has been a consensus that disease with the most significant reduction of risk due to taking aspirin is colorectal cancer. Gastrointestinal cancer also benefits from the effects of aspirin. This cancer of the gastrointestinal tract includes the stomach, pancreas, small and large intestine, rectum, and anus. All of which typically start with an inflammatory reaction. Think of a combo Aspirin/Brilacidin.
If you are over 50-years-old, you are at risk for conditions such as heart attack and stroke. If you take the recommended daily dose of aspirin, you reduce the risk of many age-related conditions. It is most important to take aspirin between the ages of 50 to 60. If you have remained healthy and disease free, physicians recommend it for another ten years. Your physician should advise you on what and how much you should be taking.
Innovation Pharma has evaluated Brilacidin, under Fast Track designation, in a Phase 2 clinical trial as an oral rinse to attenuate Oral Mucositis in patients with Head and Neck Cancer (HNC) who have received chemoradiation. Study results indicate Brilacidin has a high potential for preventative treatment, as evidenced by a clear reduction of Severe OM (SOM) among patients on Brilacidin as compared to those on placebo. Additional secondary endpoint analysis, showing Brilacidin delayed the onset as well as reduced the duration of SOM, supports the drug candidate's therapeutic effect. The Company and the U.S. Food and Drug Administration (FDA) have completed an End-of-Phase 2 meeting. Both parties agreed to an acceptable Brilacidin Phase 3 development pathway. The total Brilacidin oral mucositis market opportunity in HNC annually in the U.S. and Europe is estimated to be approximately $600 million to $1.2 billion. There are no effective medical treatment as I write this today only palliative measures.
Innovation Pharma also also tested Brilacidin, administered with water in an enema, in patients with Ulcerative Proctitis/Ulcerative Proctosigmoiditis (UP/UPS) — a type of Ulcerative Colitis (UC), and, like Crohn's Disease, an Inflammatory Bowel Disease (IBD) — in a proof-of-concept Phase 2 clinical trial. Topline findings support Brilacidin as a novel, non-corticosteriod, non-biologic IBD treatment, with a majority of patients treated achieving induction of clinical remission. Formulation development plans include oral tablets for the treatment of UC and Crohn's. Of note, the academic literature suggests a defensin/mucin deficiency in IBD, impacting the mucosal immune system, indicating Brilacidin may have a compensatory effect in this regard. IBD global numbers are between 6-8,000,000 people and annual cost of $22,987 per patient translates to $160,909,000,000 (Billion) per annum.
Brilacidin may have other applications in treating dermatological disorders. A key aspect of Brilacidin's mechanism of action, inhibiting Phosphodiesterase 4 (PDE4), may further support its use in treating other chronic autoimmune conditions.
As a late-stage antibiotic drug candidate, the first in a new class of anti-infectives, Brilacidin is being advanced in the clinic under Qualified Infectious Disease Product (QIDP) designation — qualifying the drug candidate for Fast Track and Priority Review, as well as an extra 5 years of market exclusivity upon drug approval. A Phase 2b trial was completed evaluating Brilacidin as an intravenously-administered medication in treating Acute Bacterial Skin and Skin Structure Infection (ABSSSI). Trial data showed a single dose of Brilacidin to be comparable in safety and efficacy to a 7-day dosing regimen of FDA-approved Daptomycin.
With the RBL data already disclosed many more virus classes will be studied that B will most likely be able to treat and cure. Being able to have a drug for the common cold virus boggles the mind of what revenue stream that could include. The safety and efficacy are already known Ipix just needs to commence phase 3 clinical trials for FDA and CDC approval. So IMO the question is not if it will happen but “WHEN”.
And that’s just for the B applications! I have been long and strong for nearly 10 years and it was Kevetrin that excited me to invest. Parenthetically speaking I've never sold a single share.I’ll discuss K at another time. I know this was a long diatribe, but one that I felt old and new investors should either be reminded of to "know what you own" just as justthefactsman has eloquently stated in his postings. All the best Billy10us.
